TEM Stock Chart & Stats
$1187.00
-$61.00(-7.47%)
At close: 4:00 PM EDT
$1187.00
-$61.00(-7.47%)
Day’s Range― - ―
52-Week Range$607.00 - $1,905.00
Previous CloseN/A
Volume9.58K
Average Volume (3M)1.80K
Market Cap
$197.93B
Enterprise Value$11.19K
Total Cash (Recent Filing)$815.99M
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 10, 2026EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares OutstandingN/A
10 Day Avg. Volume98
30 Day Avg. Volume1,804
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-41.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,114.75Price Target Upside-6.09% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-3.56
Revenue Forecast (FY)$27.11B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginsRapid revenue expansion and high gross margins indicate strong demand for Tempus’s clinical and data offerings. These economics provide a foundation for operating leverage as the company scales its platform and moves toward sustained profitability.
Expanding Data And Life-Sciences PlatformGrowth in data licensing and applications validates Tempus’s monetization of its clinical and molecular dataset. Recurring partnerships with biopharma organizations can broaden revenue beyond diagnostics and strengthen the platform’s strategic relevance.
FDA-Cleared AI Product ExpansionRegulatory clearance expands Tempus beyond oncology into cardiovascular decision support and demonstrates its ability to commercialize regulated AI products. A broader product portfolio can increase clinical adoption and diversify future growth opportunities.
Bears Say
Persistent Operating And Net LossesTempus has not yet established consistent operating profitability below its strong gross margin. Continued losses could require prolonged investment, limit financial flexibility, and make the long-term value of revenue growth dependent on successful cost scaling.
Negative Operating And Free Cash FlowOngoing cash consumption means the business is not currently funding expansion internally. Reliance on financing capacity could constrain strategic investment or increase dilution and funding risk if profitability is delayed or operating needs rise.
High Leverage And Limited Financial FlexibilityDebt materially exceeds equity while the company remains loss-making, leaving less room to absorb execution setbacks. Elevated leverage may increase refinancing pressure and restrict flexibility for acquisitions, research, and platform investment.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $607.00 and its highest was $1905.00 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $197.93B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Nov 10, 2026 which is in 62 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$2.432 by $1.752.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Overvalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -1.24.
How many shares outstanding does Tempus AI, Inc. Class A have?
Currently, no data Available
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.68 in its last earnings report, beating expectations of -$2.432. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in MX:TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,114.75 (-6.09% Downside)
$1,114.75 (-6.09% Downside)
Blogger Sentiment
Bullish
MX:TEM Sentiment 90%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.View all MX:TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$1,114.75
▼(-6.09% Downside)